What are the key takeaways from this a16z Podcast episode?

Key insights include: **China's trial volume lead:** China went from near-zero clinical trials before 2016 to surpassing the US in total volume within a few years. For novel gene therapies entering phase one in 2025, China ran roughly six times more first-ever trials than the US, indicating the lead is widest precisely at the innovation frontier where strategic advantage matters most.; **Regulatory reform blueprint:** China's 2016 reforms cut drug review backlogs from roughly 600 days to a 65-day target by consolidating regional accreditation into one national framework, allowing parallel ethics committee approvals across sites, and shifting government inspections to a single end-of-trial audit rather than multiple checkpoints throughout the development process.; **Trial size and error rates:** Chinese clinical trials enroll larger average populations than US trials, directly reducing both false positive and false negative results. Bigger enrollment lowers type one and type two error rates simultaneously, meaning fewer viable drugs get abandoned for statistical reasons and fewer ineffective drugs advance — a structural quality advantage compounding over time.

What did Theo Jaffe and Gabriel Dickinson discuss on a16z Podcast?

Researcher Cremieux Recueil presents data showing China has surpassed the US in clinical trial volume and novel drug development since 2016 reforms. The episode examines how regulatory redesign, trial structure, and drug reimbursement innovation drove this shift, and what it means for American biomedical leadership. Key topics include: **China's trial volume lead:** China went from near-zero clinical trials before 2016 to surpassing the US in total volume within a few years. For novel gene therapies entering phase one in 2025, China ran roughly six times more first-ever trials than the US, indicating the lead is widest precisely at the innovation frontier where strategic advantage matters most.; **Regulatory reform blueprint:** China's 2016 reforms cut drug review backlogs from roughly 600 days to a 65-day target by consolidating regional accreditation into one national framework, allowing parallel ethics committee approvals across sites, and shifting government inspections to a single end-of-trial audit rather than multiple checkpoints throughout the development process..

How long is this episode of a16z Podcast?

This episode is 57 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

a16z Podcast

The Shift in Global Drug Development

April 29, 2026

57 min episode · 2 min read

Theo Jaffe,Gabriel Dickinson

Episode

57 min

Read time

2 min

Topics

Relationships, Investing, Leadership

AI-Generated Summary

Published Apr 29, 2026

Key Takeaways

✓China's trial volume lead: China went from near-zero clinical trials before 2016 to surpassing the US in total volume within a few years. For novel gene therapies entering phase one in 2025, China ran roughly six times more first-ever trials than the US, indicating the lead is widest precisely at the innovation frontier where strategic advantage matters most.
✓Regulatory reform blueprint: China's 2016 reforms cut drug review backlogs from roughly 600 days to a 65-day target by consolidating regional accreditation into one national framework, allowing parallel ethics committee approvals across sites, and shifting government inspections to a single end-of-trial audit rather than multiple checkpoints throughout the development process.
✓Trial size and error rates: Chinese clinical trials enroll larger average populations than US trials, directly reducing both false positive and false negative results. Bigger enrollment lowers type one and type two error rates simultaneously, meaning fewer viable drugs get abandoned for statistical reasons and fewer ineffective drugs advance — a structural quality advantage compounding over time.
✓Drug reimbursement market design: China negotiates drug prices down while simultaneously guaranteeing higher sales volume to pharmaceutical companies, resulting in lower government expenditure alongside higher corporate profits. Competing firms show no negative spillover effects. Areas targeted by these negotiations then attract increased clinical trial investment, creating a self-reinforcing cycle of lower prices and more innovation.
✓US structural headwinds: US pharmaceutical returns already fall below the cost of capital, making self-financing of innovation difficult. The proposed Most Favored Nation pricing policy would further compress profits. Regulatory inconsistency — where the CBER approved trial designs but later rejected results — undermines company planning. Awareness gaps mean firms are not exploiting existing deregulation that has already occurred.

What It Covers

Researcher Cremieux Recueil presents data showing China has surpassed the US in clinical trial volume and novel drug development since 2016 reforms. The episode examines how regulatory redesign, trial structure, and drug reimbursement innovation drove this shift, and what it means for American biomedical leadership.

Key Questions Answered

•China's trial volume lead: China went from near-zero clinical trials before 2016 to surpassing the US in total volume within a few years. For novel gene therapies entering phase one in 2025, China ran roughly six times more first-ever trials than the US, indicating the lead is widest precisely at the innovation frontier where strategic advantage matters most.
•Regulatory reform blueprint: China's 2016 reforms cut drug review backlogs from roughly 600 days to a 65-day target by consolidating regional accreditation into one national framework, allowing parallel ethics committee approvals across sites, and shifting government inspections to a single end-of-trial audit rather than multiple checkpoints throughout the development process.
•Trial size and error rates: Chinese clinical trials enroll larger average populations than US trials, directly reducing both false positive and false negative results. Bigger enrollment lowers type one and type two error rates simultaneously, meaning fewer viable drugs get abandoned for statistical reasons and fewer ineffective drugs advance — a structural quality advantage compounding over time.
•Drug reimbursement market design: China negotiates drug prices down while simultaneously guaranteeing higher sales volume to pharmaceutical companies, resulting in lower government expenditure alongside higher corporate profits. Competing firms show no negative spillover effects. Areas targeted by these negotiations then attract increased clinical trial investment, creating a self-reinforcing cycle of lower prices and more innovation.
•US structural headwinds: US pharmaceutical returns already fall below the cost of capital, making self-financing of innovation difficult. The proposed Most Favored Nation pricing policy would further compress profits. Regulatory inconsistency — where the CBER approved trial designs but later rejected results — undermines company planning. Awareness gaps mean firms are not exploiting existing deregulation that has already occurred.

Notable Moment

Cremieux reveals that China's drug reimbursement negotiations produce an outcome that defies standard economic expectations: pharmaceutical companies end up more profitable after price cuts, not less, because government-guaranteed volume increases outpace the margin reduction — a result with no measurable negative spillover on competing firms.

Know someone who'd find this useful?

Episode Transcript

America is 4% of the world population, it's about 13% of all the drug buying but it's also more than half of the sales in terms of dollar amounts. So it's huge and this is a big advantage because like, you know, innovation does respond to the money and it has to. We're more likely to have false positives and false negatives in our trials because they are smaller than theirs. Theirs are less likely to have both. The type one and type two error rates are both down for China because they run bigger better trials. China says, well, no. We're gonna make you profitable. We're actually gonna make you money. If you are a firm that we are negotiating with and you lower those costs, we're gonna help you sell more so that you don't have a reduction in your profit so that you become more profitable, and we pay less money, and everybody's just better off in general. What happens when The United States is no longer the leader in biomedical innovation? For decades, The US dominated drug development, producing a large share of the world's new therapies and setting the pace for clinical research. But over the last few years, that started to change. China has rapidly expanded its clinical trial system, accelerated approvals, and is now leading in both volume and novel drug development. This shift isn't about scale, it's about systems, regulatory design, trial structure, funding models, and incentives all shape how quickly new treatments reach patients and where innovation happens. The question now is whether The US can adapt or whether the center of gravity for biotech continues to move. Theo Jaffe and Gabriel Dickinson speak with Cremieux. Welcome to MTS Cremieux Recue. How do you pronounce it in the French? Cremey reche. Cremey reche. That was pretty good. We're gonna add you That was like a that you had a slight Canadian accent there. To the tweet wall. Uh-oh. Straight out of the tweet wall. Let me make this bigger so I can look at that. Nothing ever happens. That's what it says. That's the the watch word at MTS. Welcome to MTS. Nothing ever happens. Here are the situations. Alright. Great. So are we live right now? We are. We are live right now, Creme. We are live on MTS. It's so good to have you on the show. Thank you so much. I'm saying Creme because Cremeaux, those last, like, four vowels there, three vowels are just like, they're scared. They're scaring me. And Australians, we already struggle with vowels. It's already a challenge for my people. So, so, Cremo, I mean, great to have you on. Theo and I are very pleased to have you on. And we were just like, come on the show. Let's let's chat. And you were like, I'm gonna come on the show, and I'm gonna talk about clinical trials. Yeah. You were like, sure. Sure. Sure. Let's learn. We're all gonna learn a …

Get the full transcript (11,844 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all a16z Podcast transcripts →